Advances in second-generation androgen receptor inhibitors for advanced prostate cancer
10.12483/j.issn.1009-8291.2026.02.017
- VernacularTitle:第二代雄激素受体抑制剂在晚期前列腺癌的研究新进展
- Author:
Baojun WANG
1
;
Junnan XU
1
;
Shaoxi NIU
1
;
Zhuoran LI
1
;
Zhiqiang CHEN
1
;
Zhuo JIA
1
;
Xu ZHANG
1
Author Information
1. Department of Urology, The First Medical Centre, Chinese PLA General Hospital, Beijing 100853, China
- Publication Type:Journal Article
- Keywords:
advanced prostate cancer;
novel hormone therapy;
second-generation androgen receptor inhibitors;
androgen deprivation therapy
- From:
Journal of Modern Urology
2026;31(2):193-198
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is a prevalent malignant tumor of the male genitourinary system in China, with a persistently elevated incidence rate.Given the insidious onset, propensity for metastasis in advanced stages, and poor efficacy of traditional treatments, new hormone therapies have garnered increasing attention in recent years.A number of clinical studies have demonstrated that second-generation androgen receptor inhibitors (SGARIs), including enzalutamide, apalutamide, darolutamide, and rezvilutamide, can be beneficial in different stages of advanced prostate cancer.Furthermore, their early application has been shown to delay disease progression while maintaining a controlled safety profile.At present, SGARIs have increasingly become the primary therapeutic agents for advanced prostate cancer in various stages.This article reviews the clinical research progress of SGARIs in recent years, with the aim of offering valuable clinical reference for clinicians.
